Literature DB >> 22327624

KIF5B-RET fusions in lung adenocarcinoma.

Takashi Kohno1, Hitoshi Ichikawa, Yasushi Totoki, Kazuki Yasuda, Masaki Hiramoto, Takao Nammo, Hiromi Sakamoto, Koji Tsuta, Koh Furuta, Yoko Shimada, Reika Iwakawa, Hideaki Ogiwara, Takahiro Oike, Masato Enari, Aaron J Schetter, Hirokazu Okayama, Aage Haugen, Vidar Skaug, Suenori Chiku, Itaru Yamanaka, Yasuhito Arai, Shun-Ichi Watanabe, Ikuo Sekine, Seishi Ogawa, Curtis C Harris, Hitoshi Tsuda, Teruhiko Yoshida, Jun Yokota, Tatsuhiro Shibata.   

Abstract

We identified in-frame fusion transcripts of KIF5B (the kinesin family 5B gene) and the RET oncogene, which are present in 1-2% of lung adenocarcinomas (LADCs) from people from Japan and the United States, using whole-transcriptome sequencing. The KIF5B-RET fusion leads to aberrant activation of RET kinase and is considered to be a new driver mutation of LADC because it segregates from mutations or fusions in EGFR, KRAS, HER2 and ALK, and a RET tyrosine kinase inhibitor, vandetanib, suppresses the fusion-induced anchorage-independent growth activity of NIH3T3 cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22327624      PMCID: PMC6430196          DOI: 10.1038/nm.2644

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  18 in total

Review 1.  Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Authors:  Filip Janku; David J Stewart; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

Review 2.  Triggers for genomic rearrangements: insights into genomic, cellular and environmental influences.

Authors:  Ram-Shankar Mani; Arul M Chinnaiyan
Journal:  Nat Rev Genet       Date:  2010-11-03       Impact factor: 53.242

Review 3.  Kinesin superfamily motor proteins and intracellular transport.

Authors:  Nobutaka Hirokawa; Yasuko Noda; Yosuke Tanaka; Shinsuke Niwa
Journal:  Nat Rev Mol Cell Biol       Date:  2009-10       Impact factor: 94.444

Review 4.  The RET proto-oncogene in human cancers.

Authors:  S M Jhiang
Journal:  Oncogene       Date:  2000-11-20       Impact factor: 9.867

5.  Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

Authors:  Hisayuki Shigematsu; Takao Takahashi; Masaharu Nomura; Kuntal Majmudar; Makoto Suzuki; Huei Lee; Ignacio I Wistuba; Kwun M Fong; Shinichi Toyooka; Nobuyoshi Shimizu; Takehiko Fujisawa; John D Minna; Adi F Gazdar
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

Review 6.  Targeting the RET pathway in thyroid cancer.

Authors:  Samuel A Wells; Massimo Santoro
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

7.  Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.

Authors:  Justin A Bishop; Rajni Sharma; Peter B Illei
Journal:  Hum Pathol       Date:  2009-09-08       Impact factor: 3.466

8.  The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.

Authors:  Donata Vitagliano; Valentina De Falco; Anna Tamburrino; Sabrina Coluzzi; Giancarlo Troncone; Gennaro Chiappetta; Fortunato Ciardiello; Giampaolo Tortora; James A Fagin; Anderson J Ryan; Francesca Carlomagno; Massimo Santoro
Journal:  Endocr Relat Cancer       Date:  2010-11-30       Impact factor: 5.678

9.  Vandetanib: first global approval.

Authors:  Helen Commander; Glenn Whiteside; Caroline Perry
Journal:  Drugs       Date:  2011-07-09       Impact factor: 9.546

10.  ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Authors:  Francesca Carlomagno; Donata Vitagliano; Teresa Guida; Fortunato Ciardiello; Giampaolo Tortora; Giancarlo Vecchio; Anderson J Ryan; Gabriella Fontanini; Alfredo Fusco; Massimo Santoro
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

View more
  306 in total

1.  Chipping away at the lung cancer genome.

Authors:  William Pao; Katherine E Hutchinson
Journal:  Nat Med       Date:  2012-03-06       Impact factor: 53.440

2.  Genetics: Gene fusion power.

Authors:  M Teresa Villanueva
Journal:  Nat Rev Clin Oncol       Date:  2012-02-28       Impact factor: 66.675

Review 3.  Patterns of Chromosomal Aberrations in Solid Tumors.

Authors:  Marian Grade; Michael J Difilippantonio; Jordi Camps
Journal:  Recent Results Cancer Res       Date:  2015

Review 4.  RET fusion gene: translation to personalized lung cancer therapy.

Authors:  Takashi Kohno; Koji Tsuta; Katsuya Tsuchihara; Takashi Nakaoku; Kiyotaka Yoh; Koichi Goto
Journal:  Cancer Sci       Date:  2013-10-01       Impact factor: 6.716

5.  Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.

Authors:  Cristina R Antonescu; Albert J H Suurmeijer; Lei Zhang; Yun-Shao Sung; Achim A Jungbluth; William D Travis; Hikmat Al-Ahmadie; Christopher D M Fletcher; Rita Alaggio
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

Review 6.  Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.

Authors:  Takashi Kohno; Takashi Nakaoku; Koji Tsuta; Katsuya Tsuchihara; Shingo Matsumoto; Kiyotaka Yoh; Koichi Goto
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 7.  To bud or not to bud: the RET perspective in CAKUT.

Authors:  T Keefe Davis; Masato Hoshi; Sanjay Jain
Journal:  Pediatr Nephrol       Date:  2014-04       Impact factor: 3.714

Review 8.  New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).

Authors:  Alessandro Russo; Ana Rita Lopes; Michael G McCusker; Sandra Gimenez Garrigues; Giuseppina R Ricciardi; Katherine E Arensmeyer; Katherine A Scilla; Ranee Mehra; Christian Rolfo
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

9.  A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Authors:  Alexander Drilon; Siqing Fu; Manish R Patel; Marwan Fakih; Ding Wang; Anthony J Olszanski; Daniel Morgensztern; Stephen V Liu; Byoung Chul Cho; Lyudmila Bazhenova; Cristina P Rodriguez; Robert C Doebele; Antoinette Wozniak; Karen L Reckamp; Tara Seery; Petros Nikolinakos; Zheyi Hu; Jennifer W Oliver; Denise Trone; Katherine McArthur; Rupal Patel; Pratik S Multani; Myung-Ju Ahn
Journal:  Cancer Discov       Date:  2018-11-28       Impact factor: 39.397

10.  The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinoma.

Authors:  Lucy F Stead; Stefano Berri; Henry M Wood; Philip Egan; Caroline Conway; Catherine Daly; Kostas Papagiannopoulos; Pamela Rabbitts
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.